Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002037896 | SCV002233849 | pathogenic | Mitochondrial complex II deficiency, nuclear type 1; Paragangliomas 5 | 2022-06-08 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Tyr211*) in the SDHA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SDHA are known to be pathogenic (PMID: 22974104, 24781757). For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. This variant has not been reported in the literature in individuals affected with SDHA-related conditions. This variant is not present in population databases (gnomAD no frequency). |
Ambry Genetics | RCV002361297 | SCV002657288 | pathogenic | Hereditary cancer-predisposing syndrome | 2021-06-04 | criteria provided, single submitter | clinical testing | The p.Y211* pathogenic mutation (also known as c.633T>G), located in coding exon 6 of the SDHA gene, results from a T to G substitution at nucleotide position 633. This changes the amino acid from a tyrosine to a stop codon within coding exon 6. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |